Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022…
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors…
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27,…
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet…
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate…
Montrouge, France, December 23, 2022 DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial …
Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive…
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel…
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable…
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid…